|
JP2009539403A
(ja)
|
2006-06-13 |
2009-11-19 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
癌を診断および処置するための組成物および方法
|
|
JP5618544B2
(ja)
|
2007-01-24 |
2014-11-05 |
オンコメッドファーマシューティカルズ インコーポレイテッド |
癌の診断および処置のための組成物および方法
|
|
SI2307051T1
(sl)
|
2008-07-08 |
2015-04-30 |
Oncomed Pharmaceuticals, Inc. |
Notch-vezavna sredstva in antagonisti ter postopki njihove uporabe
|
|
PE20121398A1
(es)
|
2009-12-10 |
2012-10-26 |
Hoffmann La Roche |
Anticuerpos ligantes preferentemente al dominio extracelular 4 de csf1r humano
|
|
US10626399B2
(en)
|
2010-01-28 |
2020-04-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
|
|
US20160208011A1
(en)
|
2010-01-28 |
2016-07-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
|
|
US10487148B2
(en)
|
2010-01-28 |
2019-11-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for treating aging-associated impairments
|
|
CN102918060B
(zh)
|
2010-03-05 |
2016-04-06 |
霍夫曼-拉罗奇有限公司 |
抗人csf-1r抗体及其用途
|
|
CA2789071C
(en)
|
2010-03-05 |
2018-03-27 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
|
SI2566517T1
(sl)
|
2010-05-04 |
2019-01-31 |
Five Prime Therapeutics, Inc. |
Protitelesa, ki vežejo CSF1R
|
|
US9161968B2
(en)
|
2011-04-08 |
2015-10-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
|
|
CA2841013C
(en)
|
2011-07-18 |
2020-04-21 |
Morphosys Ag |
Use of c-fms antagonists
|
|
WO2013059885A2
(en)
|
2011-10-28 |
2013-05-02 |
Cephalon Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
MX356337B
(es)
*
|
2011-12-15 |
2018-05-23 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
|
JP6416630B2
(ja)
*
|
2012-02-06 |
2018-10-31 |
ジェネンテック， インコーポレイテッド |
Ｃｓｆ１ｒ阻害剤を用いるための組成物及び方法
|
|
US9708601B2
(en)
|
2012-04-26 |
2017-07-18 |
Vaccinex, Inc. |
Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
|
|
AU2015264860B2
(en)
*
|
2012-05-11 |
2017-03-02 |
Five Prime Therapeutics, Inc. |
Method of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
|
|
US20130302322A1
(en)
*
|
2012-05-11 |
2013-11-14 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
RU2670743C9
(ru)
*
|
2012-05-11 |
2018-12-19 |
Файв Прайм Терапьютикс, Инк. |
Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
|
|
US20140079699A1
(en)
*
|
2012-08-31 |
2014-03-20 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
RS57120B1
(sr)
*
|
2012-10-03 |
2018-06-29 |
Chiome Bioscience Inc |
Anti-humano dlk-1 antitelo koje ima in vivo aktivnost protiv tumora
|
|
AU2014222509A1
(en)
*
|
2013-02-28 |
2015-10-01 |
University Court Of The University Of Edinburgh |
CSF1 therapeutics
|
|
CA2907973A1
(en)
|
2013-04-12 |
2014-10-16 |
Morphosys Ag |
Antibodies targeting m-csf
|
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
|
GB201315487D0
(en)
*
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
US10905779B2
(en)
|
2013-12-09 |
2021-02-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for screening human blood products comprising plasma using immunocompromised rodent models
|
|
CN106163530A
(zh)
|
2013-12-09 |
2016-11-23 |
小利兰·斯坦福大学托管委员会 |
用于治疗衰老相关病症的方法和组合物
|
|
DK3466949T3
(da)
|
2013-12-24 |
2021-03-15 |
Bristol Myers Squibb Co |
Tricyklisk forbindelse som anticancermidler
|
|
US20170023576A1
(en)
*
|
2014-04-04 |
2017-01-26 |
Oncomed Pharmaceuticals, Inc. |
Notch3 antibodies and uses thereof
|
|
HUE047385T2
(hu)
|
2014-06-06 |
2020-04-28 |
Bristol Myers Squibb Co |
Antitestek glükokortikoid indukált tumornekrózis faktor receptor (GITR) ellen és annak felhasználásai
|
|
WO2015188085A1
(en)
|
2014-06-06 |
2015-12-10 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
|
MX2016016664A
(es)
*
|
2014-06-23 |
2017-03-20 |
Five Prime Therapeutics Inc |
Metodos para tratar condiciones con anticuerpos que enlazan al receptor de factor 1 estimulador de colonias (csf1r).
|
|
AU2015339306B2
(en)
|
2014-10-29 |
2021-07-22 |
Bristol-Myers Squibb Company |
Combination therapy for cancer
|
|
AR102537A1
(es)
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
|
CA2964276A1
(en)
|
2014-11-05 |
2016-05-12 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
|
TWI758928B
(zh)
|
2014-11-21 |
2022-03-21 |
美商必治妥美雅史谷比公司 |
抗cd73抗體及其用途
|
|
CN107257806B
(zh)
*
|
2014-12-22 |
2021-08-10 |
戊瑞治疗有限公司 |
用于治疗pvns的抗csf1r抗体
|
|
AR103232A1
(es)
|
2014-12-22 |
2017-04-26 |
Bristol Myers Squibb Co |
ANTAGONISTAS DE TGFbR
|
|
JP6180663B2
(ja)
|
2014-12-23 |
2017-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｔｉｇｉｔに対する抗体
|
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
|
SG11201705484WA
(en)
*
|
2015-02-09 |
2017-08-30 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
|
EP3265454B1
(en)
|
2015-03-02 |
2020-02-26 |
Rigel Pharmaceuticals, Inc. |
Tgf-beta inhibitors
|
|
JP2018516238A
(ja)
|
2015-04-03 |
2018-06-21 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法
|
|
WO2016162505A1
(en)
|
2015-04-08 |
2016-10-13 |
F-Star Biotechnology Limited |
Her2 binding agent therapies
|
|
HUE053903T2
(hu)
|
2015-04-13 |
2021-07-28 |
Five Prime Therapeutics Inc |
Kombinációs terápia rák ellen
|
|
EP3294736B1
(en)
|
2015-05-11 |
2020-07-22 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
US10174024B2
(en)
|
2015-05-12 |
2019-01-08 |
Bristol-Myers Squibb Company |
5H-pyrido[3,2-B]indole compounds as anticancer agents
|
|
EP3303390A1
(en)
*
|
2015-05-27 |
2018-04-11 |
UCB Biopharma SPRL |
Method for the treatment of neurological disease
|
|
WO2016196228A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Antibodies against ox40 and uses thereof
|
|
CN113855804A
(zh)
|
2015-06-15 |
2021-12-31 |
小利兰·斯坦福大学托管委员会 |
用于治疗衰老相关病症的方法和组合物
|
|
JP6621252B2
(ja)
*
|
2015-06-17 |
2019-12-18 |
国立大学法人北海道大学 |
治療耐性がんに対する治療耐性低減剤
|
|
WO2017004016A1
(en)
|
2015-06-29 |
2017-01-05 |
The Rockefeller University |
Antibodies to cd40 with enhanced agonist activity
|
|
US10399987B2
(en)
|
2015-07-28 |
2019-09-03 |
Bristol-Myer Squibb Company |
TGF beta receptor antagonists
|
|
EP3341372A1
(en)
|
2015-08-25 |
2018-07-04 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
|
KR20180054701A
(ko)
*
|
2015-09-16 |
2018-05-24 |
아블렉시스, 엘엘씨 |
항-cd115 항체
|
|
US10584160B2
(en)
|
2015-09-23 |
2020-03-10 |
Bristol-Myers Squibb Company |
Glypican-3-binding fibronectin based scaffold molecules
|
|
WO2017087678A2
(en)
|
2015-11-19 |
2017-05-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
|
KR20180094036A
(ko)
|
2015-12-15 |
2018-08-22 |
브리스톨-마이어스 스큅 컴퍼니 |
Cxcr4 수용체 길항제
|
|
SG10201913033UA
(en)
|
2016-03-04 |
2020-03-30 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
|
WO2017184619A2
(en)
|
2016-04-18 |
2017-10-26 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
|
EP3995141B1
(en)
|
2016-04-28 |
2024-01-03 |
Alkahest, Inc. |
Plasma fractions as therapy for thymic cancer
|
|
JP2019519485A
(ja)
|
2016-05-04 |
2019-07-11 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
|
|
KR20190004743A
(ko)
|
2016-05-04 |
2019-01-14 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
|
CN109414421A
(zh)
|
2016-05-04 |
2019-03-01 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
|
CN109348714A
(zh)
|
2016-05-04 |
2019-02-15 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
|
KR20190004742A
(ko)
|
2016-05-04 |
2019-01-14 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
|
RU2756236C2
(ru)
|
2016-06-20 |
2021-09-28 |
Кимаб Лимитед |
PD-L1 специфические антитела
|
|
PE20190418A1
(es)
|
2016-07-14 |
2019-03-19 |
Bristol Myers Squibb Co |
Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
|
|
US20190292179A1
(en)
|
2016-07-21 |
2019-09-26 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
|
JP7128177B2
(ja)
|
2016-08-02 |
2022-08-30 |
バクシネックス インコーポレーティッド |
ワクシニアウイルス／真核細胞においてポリヌクレオチドライブラリを生成するための改善された方法
|
|
EP3504239B1
(en)
|
2016-08-25 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
|
|
EP3503916A1
(en)
|
2016-08-26 |
2019-07-03 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
JP2019528301A
(ja)
|
2016-08-26 |
2019-10-10 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法
|
|
EA039316B1
(ru)
|
2016-10-24 |
2022-01-12 |
Алкахест, Инк. |
Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
|
|
US10660909B2
(en)
|
2016-11-17 |
2020-05-26 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists
|
|
WO2018115051A1
(en)
|
2016-12-22 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
|
|
WO2018132279A1
(en)
|
2017-01-05 |
2018-07-19 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
|
US10399962B2
(en)
|
2017-01-20 |
2019-09-03 |
Arcus Biosciences, Inc. |
Azolopyrimidine for the treatment of cancer-related disorders
|
|
JP2017125040A
(ja)
*
|
2017-02-28 |
2017-07-20 |
ファイブ プライム セラピューティックス インコーポレイテッド |
コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
|
|
CN110709101B
(zh)
*
|
2017-03-23 |
2024-05-07 |
宾夕法尼亚大学理事会 |
抗C5a抗体及其应用
|
|
WO2018183366A1
(en)
|
2017-03-28 |
2018-10-04 |
Syndax Pharmaceuticals, Inc. |
Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
|
|
CN110709420A
(zh)
*
|
2017-03-31 |
2020-01-17 |
戊瑞治疗有限公司 |
使用抗gitr抗体的癌症组合疗法
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
AU2018256406A1
(en)
|
2017-04-19 |
2019-10-17 |
Marengo Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
CA3059939A1
(en)
|
2017-04-21 |
2018-10-25 |
Kyn Therapeutics |
Indole ahr inhibitors and uses thereof
|
|
EP4299129A3
(en)
|
2017-04-26 |
2024-03-20 |
Alkahest, Inc. |
Dosing regimen for treatment of cognitive impairments with blood plasma products
|
|
US11040068B2
(en)
|
2017-04-26 |
2021-06-22 |
Alkahest, Inc. |
Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
|
|
US11066392B2
(en)
|
2017-05-12 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
JP7090347B2
(ja)
|
2017-05-12 |
2022-06-24 |
ハープーン セラピューティクス，インク． |
メソテリン結合タンパク質
|
|
WO2018213377A1
(en)
|
2017-05-17 |
2018-11-22 |
Arcus Biosciences, Inc. |
Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
|
|
JP2020520943A
(ja)
|
2017-05-19 |
2020-07-16 |
シンダックス ファーマシューティカルズ， インコーポレイテッド |
併用療法
|
|
WO2019006283A1
(en)
|
2017-06-30 |
2019-01-03 |
Bristol-Myers Squibb Company |
AMORPHOUS AND CRYSTALLINE FORMS OF IDO INHIBITORS
|
|
KR20200032180A
(ko)
|
2017-07-28 |
2020-03-25 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
|
AU2018319016B2
(en)
|
2017-08-17 |
2023-08-31 |
Ikena Oncology, Inc. |
AHR inhibitors and uses thereof
|
|
SG11202000387YA
(en)
|
2017-08-25 |
2020-03-30 |
Five Prime Therapeutics Inc |
B7-h4 antibodies and methods of use thereof
|
|
US11667663B2
(en)
|
2017-08-31 |
2023-06-06 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
ES2945140T3
(es)
|
2017-08-31 |
2023-06-28 |
Bristol Myers Squibb Co |
Dinucleótidos cíclicos como agentes anticancerosos
|
|
EP3676279B1
(en)
|
2017-08-31 |
2021-12-01 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
CA3073531A1
(en)
*
|
2017-09-13 |
2019-03-21 |
Five Prime Therapeutics, Inc. |
Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
|
|
IL273432B
(he)
|
2017-09-22 |
2022-09-01 |
Kymera Therapeutics Inc |
מפרקי חלבון ושימושים בהם
|
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES OF THE LATEST
|
|
US11649212B2
(en)
|
2017-10-09 |
2023-05-16 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11203592B2
(en)
|
2017-10-09 |
2021-12-21 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
KR20200061399A
(ko)
|
2017-10-10 |
2020-06-02 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
|
AU2018346955A1
(en)
|
2017-10-13 |
2020-04-30 |
Harpoon Therapeutics, Inc. |
B cell maturation antigen binding proteins
|
|
US11427610B2
(en)
|
2017-10-16 |
2022-08-30 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
WO2019080889A1
(zh)
*
|
2017-10-26 |
2019-05-02 |
江苏恒瑞医药股份有限公司 |
抗csf-1r抗体、其抗原结合片段及其医药用途
|
|
CN111542544A
(zh)
|
2017-11-01 |
2020-08-14 |
百时美施贵宝公司 |
用于治疗癌症的免疫刺激性激动性抗体
|
|
ES2925450T3
(es)
|
2017-11-06 |
2022-10-18 |
Bristol Myers Squibb Co |
Compuestos de isofuranona útiles como inhibidores de HPK1
|
|
US20200377571A1
(en)
|
2017-12-08 |
2020-12-03 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
SG11202005912PA
(en)
|
2017-12-26 |
2020-07-29 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
JP7284759B2
(ja)
|
2017-12-27 |
2023-05-31 |
ブリストル－マイヤーズ スクイブ カンパニー |
抗ｃｄ４０抗体およびその使用
|
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
EP3737700A1
(en)
|
2018-01-12 |
2020-11-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
CN108276495B
(zh)
*
|
2018-01-24 |
2022-03-18 |
博生吉医药科技(苏州)有限公司 |
靶向csf1r嵌合抗原受体修饰的nk92mi细胞和t细胞及其制法和应用
|
|
WO2019147982A1
(en)
|
2018-01-26 |
2019-08-01 |
Celldex Therapeutics, Inc. |
Methods of treating cancer with dendritic cell mobilizing agents
|
|
TWI816742B
(zh)
|
2018-01-29 |
2023-10-01 |
美商維泰克斯製藥公司 |
Gcn2抑制劑及其用途
|
|
CN111867581B
(zh)
|
2018-01-29 |
2023-12-26 |
默克专利股份有限公司 |
Gcn2抑制剂及其用途
|
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
WO2019165315A1
(en)
|
2018-02-23 |
2019-08-29 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists alone or in combination
|
|
GB201803226D0
(en)
|
2018-02-28 |
2018-04-11 |
Ultrahuman Twelve Ltd |
CSF1R Binding agents
|
|
EA202091810A1
(ru)
|
2018-03-02 |
2021-01-29 |
Файв Прайм Терапьютикс, Инк. |
Антитела к b7-h4 и способы их применения
|
|
US11945834B2
(en)
|
2018-03-08 |
2024-04-02 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
JP2021518133A
(ja)
|
2018-03-21 |
2021-08-02 |
ファイブ プライム セラピューティクス， インコーポレイテッド |
酸性ｐＨでＶＩＳＴＡに結合する抗体
|
|
CN111886256A
(zh)
|
2018-03-23 |
2020-11-03 |
百时美施贵宝公司 |
抗mica和/或micb抗体及其用途
|
|
AU2019244091B2
(en)
|
2018-03-28 |
2023-12-07 |
Bristol-Myers Squibb Company |
Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
|
|
MX2020010604A
(es)
|
2018-04-12 |
2020-10-20 |
Bristol Myers Squibb Co |
Terapia de combinacion anticancer con anticuerpo antagonista del grupo de diferenciacion 73 (cd73) y anticuerpo antagonista del eje proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1).
|
|
AU2019255196A1
(en)
|
2018-04-16 |
2020-11-12 |
Arrys Therapeutics, Inc. |
EP4 inhibitors and use thereof
|
|
AU2019256460A1
(en)
*
|
2018-04-19 |
2020-11-12 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions of inhibiting CSF1R for treating allergic inflammation
|
|
US20230339891A1
(en)
|
2018-05-03 |
2023-10-26 |
Bristol-Myers Squibb Company |
Uracil derivatives as mer-axl inhibitors
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
SI3814348T1
(sl)
|
2018-06-27 |
2023-10-30 |
Bristol-Myers Squibb Company |
Substituirane naftiridinonske spojine, uporabne kot aktivatorji t celic
|
|
EP3814347B1
(en)
|
2018-06-27 |
2023-05-03 |
Bristol-Myers Squibb Company |
Naphthyridinone compounds useful as t cell activators
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
MX2021000009A
(es)
|
2018-07-09 |
2021-03-09 |
Five Prime Therapeutics Inc |
Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4).
|
|
US20220073617A1
(en)
|
2018-07-11 |
2022-03-10 |
Five Prime Therapeutics, Inc. |
Antibodies Binding to Vista at Acidic pH
|
|
CN108948199B
(zh)
*
|
2018-07-18 |
2019-06-21 |
博奥信生物技术（南京）有限公司 |
抗人csf-1r单克隆抗体及其用途
|
|
CN109053887B
(zh)
*
|
2018-07-18 |
2019-07-23 |
博奥信生物技术（南京）有限公司 |
一种抗人csf-1r单克隆抗体及用途
|
|
CN108948198B
(zh)
*
|
2018-07-18 |
2020-09-01 |
博奥信生物技术（南京）有限公司 |
抗人csf-1r单克隆抗体及其应用
|
|
US20210299126A1
(en)
|
2018-07-23 |
2021-09-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US20210355113A1
(en)
|
2018-07-23 |
2021-11-18 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
JP2021534101A
(ja)
|
2018-08-09 |
2021-12-09 |
ヴェルソー セラピューティクス， インコーポレイテッド |
Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
|
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
JP7425049B2
(ja)
|
2018-09-25 |
2024-01-30 |
ハープーン セラピューティクス，インク． |
Ｄｌｌ３結合タンパク質および使用方法
|
|
CN113164777A
(zh)
|
2018-09-27 |
2021-07-23 |
马伦戈治疗公司 |
Csf1r/ccr2多特异性抗体
|
|
CN113164780A
(zh)
|
2018-10-10 |
2021-07-23 |
泰洛斯治疗公司 |
抗lap抗体变体及其用途
|
|
JP2022505915A
(ja)
|
2018-10-26 |
2022-01-14 |
アルカヘスト，インコーポレイテッド |
疼痛、創傷治癒及び術後回復の改善のための血漿及び血漿画分の使用
|
|
KR20210092769A
(ko)
|
2018-11-16 |
2021-07-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항-nkg2a 항체 및 그의 용도
|
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
US20220016168A1
(en)
|
2018-12-11 |
2022-01-20 |
Celldex Therapeutics, Inc. |
Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
|
|
CN113301960A
(zh)
*
|
2018-12-13 |
2021-08-24 |
财团法人生物技术开发中心 |
抗人类csf-1r抗体和其用途
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
JP2019089840A
(ja)
*
|
2019-02-22 |
2019-06-13 |
ファイブ プライム セラピューティックス インコーポレイテッド |
コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
|
|
AU2020242284A1
(en)
|
2019-03-19 |
2021-09-16 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Combination therapy for the treatment of cancer
|
|
AU2020253990A1
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
|
MA55565A
(fr)
|
2019-04-05 |
2022-02-09 |
Kymera Therapeutics Inc |
Agents de dégradation de stat et leurs utilisations
|
|
WO2020231766A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
US20230242478A1
(en)
|
2019-05-13 |
2023-08-03 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
EP3976832A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
EP3977132A1
(en)
|
2019-05-30 |
2022-04-06 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
CN114502540A
(zh)
|
2019-05-31 |
2022-05-13 |
医肯纳肿瘤学公司 |
Tead抑制剂和其用途
|
|
CN112300277A
(zh)
*
|
2019-07-25 |
2021-02-02 |
苏州丁孚靶点生物技术有限公司 |
Csf1r抗体、基因、载体、宿主细胞和csf1r拮抗剂
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
US20220306630A1
(en)
|
2019-08-06 |
2022-09-29 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
|
JP2022548292A
(ja)
|
2019-09-19 |
2022-11-17 |
ブリストル－マイヤーズ スクイブ カンパニー |
酸性ｐＨでＶＩＳＴＡと結合する抗体
|
|
JP2022550069A
(ja)
|
2019-09-26 |
2022-11-30 |
エフ．ホフマン－ラ ロシュ アーゲー |
抗ｃｓｆ－１ｒ抗体
|
|
US11548870B2
(en)
|
2019-11-19 |
2023-01-10 |
Bristol-Myers Squibb Company |
Compounds useful as inhibitors of helios protein
|
|
MX2022006308A
(es)
|
2019-11-26 |
2022-06-22 |
Ikena Oncology Inc |
Derivados de carbazol polimorfos y usos de los mismos.
|
|
IL293357A
(he)
|
2019-11-26 |
2022-07-01 |
Bristol Myers Squibb Co |
מלחים/קוריסטלים של (r)-n-(4-כלורופניל)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
|
|
BR112022011651A2
(pt)
|
2019-12-17 |
2022-08-23 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
WO2021133752A1
(en)
|
2019-12-23 |
2021-07-01 |
Bristol-Myers Squibb Company |
Substituted heteroaryl compounds useful as t cell activators
|
|
CN115175907A
(zh)
|
2019-12-23 |
2022-10-11 |
百时美施贵宝公司 |
可用作t细胞激活剂的经取代的哌嗪衍生物
|
|
TW202136242A
(zh)
|
2019-12-23 |
2021-10-01 |
美商凱麥拉醫療公司 |
Smarca降解劑及其用途
|
|
EP4081516A1
(en)
|
2019-12-23 |
2022-11-02 |
Bristol-Myers Squibb Company |
Substituted quinazolinyl compounds useful as t cell activators
|
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
|
WO2021133748A1
(en)
|
2019-12-23 |
2021-07-01 |
Bristol-Myers Squibb Company |
Substituted quinolinonyl piperazine compounds useful as t cell activators
|
|
KR20220117320A
(ko)
*
|
2019-12-24 |
2022-08-23 |
아다젠 (수저우) 리미티드 |
항 csf1r 분자 및 이의 용도
|
|
WO2021139682A1
(en)
|
2020-01-07 |
2021-07-15 |
Hifibio (Hk) Limited |
Anti-galectin-9 antibody and uses thereof
|
|
AU2021230289A1
(en)
|
2020-03-03 |
2022-09-29 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
|
EP4118118A1
(en)
|
2020-03-09 |
2023-01-18 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
|
IL295569A
(he)
|
2020-03-19 |
2022-10-01 |
Arcus Biosciences Inc |
תרכובות טטרלין וטטרהידרוקינולין כמעכבות של hif-2alpha
|
|
JP2023518423A
(ja)
|
2020-03-19 |
2023-05-01 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｍｄｍ２分解剤およびそれらの使用
|
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
MX2022015157A
(es)
|
2020-06-02 |
2023-01-16 |
Arcus Biosciences Inc |
Anticuerpos para tigit.
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
AU2021292195A1
(en)
|
2020-06-17 |
2023-01-05 |
Arcus Biosciences, Inc. |
Crystalline forms of a CD73 inhibitor and uses thereof
|
|
JP2023532768A
(ja)
|
2020-07-07 |
2023-07-31 |
バイオエヌテック エスエー |
Ｈｐｖ陽性癌の治療用ｒｎａ
|
|
US11857535B2
(en)
|
2020-07-30 |
2024-01-02 |
Kymera Therapeutics, Inc. |
Methods of treating mutant lymphomas
|
|
KR20230074721A
(ko)
|
2020-08-17 |
2023-05-31 |
바이사이클티엑스 리미티드 |
Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
|
|
US20230303700A1
(en)
|
2020-08-31 |
2023-09-28 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
|
IL303376A
(he)
|
2020-12-02 |
2023-08-01 |
Ikena Oncology Inc |
מעכבי tead ושימושיהם
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
TW202241488A
(zh)
|
2021-01-11 |
2022-11-01 |
英商拜斯科技技術開發有限公司 |
治療癌症之方法
|
|
MX2023009059A
(es)
|
2021-02-02 |
2023-09-15 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
|
AU2022216810A1
(en)
|
2021-02-02 |
2023-08-24 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
US20240109899A1
(en)
|
2021-02-04 |
2024-04-04 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
|
KR20230145446A
(ko)
|
2021-02-15 |
2023-10-17 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak4 분해제 및 이의 용도
|
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
AU2022253450A1
(en)
|
2021-04-05 |
2023-11-16 |
Bristol-Myers Squibb Company |
Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
|
|
BR112023020077A2
(pt)
|
2021-04-06 |
2023-11-14 |
Bristol Myers Squibb Co |
Compostos de oxoisoindolina substituída por piridinila
|
|
EP4323066A1
(en)
|
2021-04-16 |
2024-02-21 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
TW202313602A
(zh)
|
2021-05-21 |
2023-04-01 |
美商阿克思生物科學有限公司 |
Axl化合物
|
|
EP4341262A1
(en)
|
2021-05-21 |
2024-03-27 |
Arcus Biosciences, Inc. |
Axl inhibitor compounds
|
|
EP4370552A1
(en)
|
2021-07-13 |
2024-05-22 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
WO2023028235A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
US20230134932A1
(en)
|
2021-08-25 |
2023-05-04 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
WO2023077046A1
(en)
|
2021-10-29 |
2023-05-04 |
Arcus Biosciences, Inc. |
Inhibitors of hif-2alpha and methods of use thereof
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2023150186A1
(en)
|
2022-02-01 |
2023-08-10 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023178329A1
(en)
|
2022-03-18 |
2023-09-21 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
WO2023215719A1
(en)
|
2022-05-02 |
2023-11-09 |
Arcus Biosciences, Inc. |
Anti-tigit antibodies and uses of the same
|
|
WO2023230205A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
US20240124490A1
(en)
|
2022-07-15 |
2024-04-18 |
Arcus Biosciences, Inc. |
Inhibitors of hpk1 and methods of use thereof
|
|
WO2024020034A1
(en)
|
2022-07-20 |
2024-01-25 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
|
WO2024036100A1
(en)
|
2022-08-08 |
2024-02-15 |
Bristol-Myers Squibb Company |
Substituted tetrazolyl compounds useful as t cell activators
|
|
WO2024036101A1
(en)
|
2022-08-09 |
2024-02-15 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
|
WO2024081385A1
(en)
|
2022-10-14 |
2024-04-18 |
Arcus Biosciences, Inc. |
Hpk1 inhibitors and methods of use thereof
|
|
WO2024086718A1
(en)
|
2022-10-20 |
2024-04-25 |
Arcus Biosciences, Inc. |
Lyophilized formulations of cd73 compounds
|